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Introduction: Pulmonary ground-glass nodules are frequently 
encountered. The purpose of this study was to evaluate the natural 
history of them and to gain some insights on how to follow them up.
Methods: We retrospectively studied patients with pulmonary nod-
ules that met the following criteria: (1) tumor diameter of 3 cm or 
less, (2) ground-glass opacity proportion of 50% or more, and (3) 
observation without treatment for 6 months or more. Between 1999 
and 2012, 108 pulmonary lesions in 61 patients fulfilled these crite-
ria. We reevaluated their computed tomography images and analyzed 
changes in their size.
Results: The tumors were 1 cm or lesser in size in 69 lesions, 1.1 cm 
to 2 cm in 34, and 2.1 cm to 3 cm in five. The proportion of solid 
lesions was 0% for 82 lesions, 1% to 25% for 19, and 26% to 50 % 
for seven. At the median observation period of 4.2 years, 29 lesions 
had become larger, whereas the remaining 79 had persisted without 
changing in size (±1 mm). The median size change in the nodules 
that grew was 7 mm (range, 2–32 mm). All 29 tumors began to grow 
within 3 years of their first observation: 1 year or lesser in 13 lesions, 
after 1.1 years to 2 years in 12, and after 2.1 years to 3 years in four.
Conclusions: Some small lung lesions exhibiting ground-glass opacity 
persisted without changes in size, whereas others grew gradually. The 
tendency to grow was clear within the first 3 years in all cases. Therefore, 
we conclude that these lesions should be followed for at least 3 years.
Key Words: Follow-up, Ground-glass opacity, Lung cancer, Small 
lung lesion.
(J Thorac Oncol. 2013;8: 309-314)
Pulmonary nodules with ground-glass opacity (GGO) have been frequently observed since the clinical introduction of 
high-resolution computed tomography (CT). GGO is defined 
as hazy opacity that does not obscure underlying bronchial 
structures or pulmonary vessels with high-resolution CT.1 
Moreover, GGO can be observed in a wide variety of clinical 
features; for example, nodular GGO is observed in malignan-
cies and in benign conditions such as focal interstitial fibrosis, 
inflammation, and hemorrhage.2 In addition, some patients 
present with multiple lesions, and it is often difficult to surgi-
cally resect all these lesions.
Lesions that contain little or no GGO are regarded as 
radiologically invasive tumors and are usually candidates for 
surgical resection.3–5 However, some lesions that contain a 
greater proportion of GGO often grow very slowly or even 
persist for years, without changes in size, and the optimal 
management of these lesions remains unclear.
In our institution surgical resection is generally not 
performed for lesions that are 2 cm or smaller in size and 
exhibit 100% GGO at the initial presentation. However, dur-
ing follow-up, many of these lesions demonstrate malignancy, 
and surgery should be considered when they begin to grow. 
However, patients who have previously undergone pulmonary 
resection or have bilateral multiple pulmonary nodules tend to 
be observed more conservatively even if the lesions are larger 
than 2 cm or contain solid component. Therefore, we decided 
the inclusion criteria of this study as pulmonary nodules that 
are 3 cm or lesser and exhibit 50% or more GGO component.
The purpose of this study was to evaluate the natural 
history of these lesions and clarify how long patients showing 
such lesions should be followed to monitor for lesion growth.
MATERIALS AND METHODS
Patient Cohort
We retrospectively studied patients with pulmonary 
nodules who met the following criteria: (1) tumor diameter 
of 3 cm or less, (2) GGO proportion of 50% or more, and 
(3) observation without treatment for 6 months or longer. 
Between 1999 and 2012, we encountered 108 pulmonary 
lesions in 61 patients who fulfilled the abovementioned 
criteria in our institution. These lesions were first detected 
at various situations: screening in 38 lesions, preoperative 
CT examination for other pulmonary lesions in 27, routine 
follow-up CT after pulmonary resection in 14, CT examination 
for disease in other organs in 29. We also reviewed the clinical 
courses of the patients who underwent pulmonary resection. 
The Institutional Review Board approved this study and 
waived the need for individual patient consent.
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Radiological Evaluation of the Lesions
A chest CT was performed for each patient. For patients 
with multiple lesions at the first presentation, only those 
lesions meeting the abovementioned criteria were included.
The maximum diameters of each lesion on the lung 
window were measured. We defined growth as an increase 
of 2 mm or more in size. We scored the GGO ratio by visu-
ally estimating the proportion of the GGO component in 
each tumor without measuring the diameter, as we previ-
ously reported.6 GGO was defined as an area with a slight, 
homogenous increase in density, which did not obscure the 
underlying vascular markings.7 We evaluated all the CT 
images during the follow-up period and analyzed changes in 
size over time. The interval between CT examinations was 
at the physician’s discretion: every 3 to 12 months. The CT 
examinations were performed with a window level of 500 
Hounsfield units (HU) to 700 HU and a window width of 
1000 HU to 2000 HU as a lung window setting for 2- to 
5-mm sections. Most CT scans were acquired with the uses 
of multidetector CT, except for nine lesions. During only the 
early period of follow-up, single-detector CT examinations 
were performed for the nine lesions.
Pathological Diagnosis
The pathological diagnosis was classified accord-
ing to the International Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory 
Society international multidisciplinary classification of lung 
adenocarcinoma.8
RESULTS
Characteristics of the Patients and 
Their Pulmonary Lesions
The characteristics of 108 pulmonary lesions that 
were observed in 61 patients at the first presentation are 
shown in table 1. Approximately two thirds of the patients 
were women and never smokers. At the time of initial obser-
vation, 19 patients (31 %) had undergone prior pulmonary 
resection and 20 patients (33 %) had bilateral multiple 
lesions. Among these 39 patients, eight patients fulfilled 
both of them. The histologic diagnoses of prior resected 
lesions included adenocarcinoma in 13 patients and prein-
vasive lesions including atypical adenomatous hyperplasia 
(AAH) and adenocarcinoma in situ (AIS) in five patients. 
In the remaining one patient the pathological diagnosis of 
the lesion was not clear because 6-mm pure GGO had been 
unsuccessfully resected by video-assisted thoracic surgery. 
The median tumor size was 0.95 cm (range, 0.4–2.5 cm). 
Approximately three fourths of the lesions exhibited 0% 
solid components and were pure GGO lesions.
Changes in Size of the 108 Pulmonary Lesions
After the median observation period of 4.2 years, 29 of 
the 108 lesions (27%) had become larger, whereas the remain-
ing 79 lesions (73%) had persisted without changing in size 
(±1 mm). The median size change in the nodules that grew 
was 7 mm (range, 2–32 mm). CT images of two representative 
pulmonary nodules with GGO are shown in Figure 1. The 
change in size of each lesion from the first presentation to the 
last CT examination is shown in Figure 2A. Even for lesions 
that were 1 cm or smaller, some became larger during this time 
period (Fig. 2B), and some pure GGO lesions also grew in 
size (Fig. 2C).
During the same observation period, the proportion of 
the solid component increased in 17 of the 108 lesions (16%). 
Of these, 14 lesions grew in size, whereas the remaining three 
lesions persisted without changing in size. The solid compo-
nent began to increase within 1 year for two of these lesions 
and during the seventh year of observation for one lesion.
Growth Tendency among the 
29 Pulmonary Lesions
To analyze the growth tendency of the 29 pulmonary 
lesions during the observation period, all changes in size 
between CT examinations were analyzed; these changes are 
TABLE 1.  Characteristics of 61 Patients and Their 108 
Lesions at the First Presentation
Characteristics Number of Patients %
Age (yr)
 Median (range) 61 (35–78)
Sex
 Male 22 36
 Female 39 64
Smoking history
 Never 40 66
 Former/current 19 31
 Unknown 2 3
Prior pulmonary resection
 Yes 19 31
 No 42 69
Bilateral multiple lesions
 Yes 20 33
 No 41 67
Number of lesions
 1 40 66
 2 10 16
 3 4 6
 4 4 6
 5 1 2
 7 1 2
 8 1 2
Number of lesions
Tumor diameter (cm)
  ≤ 1 69 64
  1.1–2 34 31
  2.1–3 5 5
Solid component (%)
  0 82 76
  1–25 19 18
  26–50 7 6
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shown in Figure 3. All 29 lesions began to grow within 3 years 
from the time of the first observation; of these, 13 lesions grew 
after within 1 year, 12 lesions grew after 1.1 years to 2 years, 
and four lesions grew after 2.1 years to 3 years.
Pulmonary Resection
Twenty-one of the studied patients, who had a total of 
26 lesions, underwent pulmonary resection (Table 2). We basi-
cally performed pulmonary resection when the lesions began 
to grow in size or the solid component began to increase. 
However, there were no clear-cut criteria because prior pulmo-
nary resection and the presence of bilateral lung lesions should 
be considered. Among the resected 26 lesions, 12 lesions grew 
in size and the median size change in them was 7.5 mm. In 
addition, relatively large lesions or part solid lesions were con-
sidered for resection even if no changes were observed. The 
remaining 14 lesions showed no changes but the median tumor 
size was 1.25 cm and six of them contained solid component.
Among 21 patients, 17 patients underwent open lung 
surgery and the remaining four underwent video-assisted 
thoracic surgery. Limited surgical resections, including 
segmentectomy and wedge resections, were performed in 
16 patients (76%). Limited resection was chosen for the 
following reasons: prior resection or bilateral lung lesions in 
nine, showing 100% GGO in six, and location which ensure 
the margin of resection by segmentectomy in one.
The histologic diagnoses mainly included preinvasive 
lesions and minimally invasive adenocarcinoma. Lymph 
nodes dissection was performed in 13 of 21 patients and all 
were diagnosed as stage IA. Epidermal growth factor receptor 
(EGFR) mutation analyses were performed in 21 lesions, 
and 19 lesions (90%) harbored EGFR mutation. Kirsten 
rat sarcoma (KRAS) mutation analyses were performed 
in 16 lesions, and all these lesions were wild type. After a 
median follow-up period of 20.1 months, all the patients who 
underwent pulmonary resection were alive without recurrence.
DISCUSSION
In this study, some of the small lung lesions exhibit-
ing GGO on CT persisted without changing in size, whereas 
FIGURE 1.  Computed tomography images of two represen-
tative pulmonary nodules with GGO. A, A part solid (1%–25 %) 
GGO lesion became larger and increased the solid compo-
nent (26%–50 %) after 3.3 years. B, However, a pure GGO 
lesion had persisted without changing in size for 6.3 years. 
GCO, ground-glass opacity.
FIGURE 2.  The changes in size of the 108 evaluated lesions, 
(A) from the time of the first presentation to the last com-
puted tomography examination. B, Some of the 69 lesions 
that were 1 cm or less in size became larger, (C), some of the 
82 pure GGO lesions also grew in size during the observation 
period. GCO, ground-glass opacity.
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others gradually grew in size over time. Moreover, the ten-
dency to grow was clear within the first 3 years in all cases. 
This study is the first report to analyze the time at which 
lesions with GGO begin to grow, and our results indicate that 
patients with such lesions should be followed for at least 3 
years to accurately evaluate lesion growth.
In cases of lung cancer, many reports have described 
correlations between radiological findings of GGO and 
pathological features. AAH and AIS are typically manifested 
as pure GGO, whereas more advanced adenocarcinomas may 
include a larger solid component within the GGO region.4,5 In 
addition, some reports have described the tumor doubling time 
(TDT) of lung tumors that exhibit mainly GGO. Hasegawa et 
al.9 reported that the mean TDT of 19 pure GGOs was 813 
days, and Aoki et al.10 reported that the mean TDT of six AIS, 
five of them exhibiting 50% or more GGO component, was 
880 days. We computationally simulated the size changes of 
small lung lesions based on these data and found that a 5-mm 
lesion would grow to 6.7 mm to 6.8 mm in size within 3 years, 
whereas a 10-mm lesion would grow to 13.3 mm to 13.6 mm 
size within the same period. These calculated changes in size 
seem to be detectable by CT analysis, and these data concur 
with our experimental data that all evaluated lesions began to 
grow within the first 3 years of observation.
We sought to evaluate the pathological differences 
between lung lesions with GGO that persisted without 
changing in size and those that gradually grew. In general, 
lung adenocarcinomas are thought to follow a linear multi-
step progression, whereby AAH progresses to AIS and is 
followed by invasive adenocarcinoma. However, Yatabe et 
al.11 suggested a novel scenario for the progression of lung 
adenocarcinoma, which does not support this linear progres-
sion schema, whereby KRAS-mutated AAH rarely progresses 
to more advanced tumors. Their scenario is based on the dis-
tribution of KRAS mutations. KRAS mutations were shown 
to decrease with progression and were detectable in 33% of 
cases of AAH, 12% of cases of AIS, 8% of minimally invasive 
adenocarcinomas, and 0% of well-differentiated adenocarci-
nomas.12 However, the overall frequency of KRAS mutations 
in lung adenocarcinoma was limited to 13%.13
With regard to the clinical aspects of these cases, 
Takigawa et al.14 reported that the prognosis of patients with 
stage IA adenocarcinoma was not significantly different from 
that of the same stage patients with additional AAH. Chapman 
et al.15 also reported similar results in patients with stage IA 
adenocarcinoma. These data suggest that not all AAHs influ-
ence overall survival.
On the basis of previous genetic and clinical reports 
and our radiological data, we hypothesize that lung GGO 
lesions demonstrating growth progress to advanced 
adenocarcinoma, whereas others without growth persist as 
AAH, which does not influence survival. Moreover, these 
lesions should be distinguished after performing at least 3 
years of CT observation, and only the former type should 
be surgically resected. Our hypothesis seems to be useful to 
reduce unnecessary resections for lesions detected in the CT 
screening. Pulmonary nodules with GGO will be detected 
increasingly because of the positive result of the National Lung 
Screening Trial in the United States.16 Moreover, Nederlands 
Leuvens Longkanker Screeningsonderzoek (NELSON), 
Dutch-Belgian randomized lung cancer screening trial, is 
ongoing in Europe.17
However, the surgical intervention strategy for lesions 
with GGO has not been established. The American Association 
for Thoracic Surgery has proposed the following recommen-
dations: (1) both pure and partially solid GGOs 10 mm or 
smaller should be followed by CT evaluation until the patient 
reaches 79 years of age, unless changes are observed; and (2) 
lesions with GGO greater than 10 mm should be either fol-
lowed by CT evaluation or considered for biopsy or surgi-
cal resection, even if no changes are observed.18 In addition, 
Asamura19 suggested the following strategy: (1) lesions that 
are 15 mm or less and exhibit 100% GGO should be observed 
by CT evaluation, whereas surgical intervention should be 
considered if overt growth or a newly developing solid com-
ponent is observed; (2) lesions that are larger than 15 mm 
and exhibit 100% GGO should observed by CT evaluation, 
whereas surgical intervention should be considered even if no 
changes are observed; and (3) partially solid GGOs should be 
resected at the time of the first presentation. However, these 
strategies do not specify how long lesions without noticeable 
changes should be monitored for growth changes.
FIGURE 3.  The changes in size of all 29 lesions that grew. 
The changes in size between CT examinations were mea-
sured to analyze each lesion’s tendency to grow. The first 
changes in size are shown with highly colored lines and 
subsequent changes are shown with light-colored lines. All 29 
lesions began to grow within the first 3 years of observation. 
CT, computed tomography.
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In clinical practice, limited surgical resection is some-
times considered for pulmonary lesions with GGO. In our 
study, 16 of 21 patients (76%) underwent limited resection 
because most of these patients had additional lesions in other 
lobes. As each of these patients survived without recurrence, 
limited resection might be reasonable for select patients. 
There are two ongoing clinical studies in Japan to assess the 
efficacy of limited surgical resection for small lung cancer 
lesions, including a phase III trial comparing lobectomy and 
segmentectomy for small radiologically invasive lung cancer20 
and a phase II trial of wedge resection for small radiologically 
noninvasive lung cancer.21
In addition, there have been several reports on the rela-
tionship between morphology and EGFR mutations in adeno-
carcinoma, and these have demonstrated AIS harboring EGFR 
mutations in 67% to 68% of the cases.22,23 Among the 21 lesions 
with EGFR mutation analyses, 19 lesions (90%) harbored EGFR 
mutation in our study, and both GGO and EGFR mutations were 
associated with adenocarcinoma histology, female sex, and non-
smoking status. Moreover, the pulmonary lesions resected in our 
study initially exhibited large GGO components and grew gradu-
ally. Although our patient cohort was highly selective, these find-
ings suggest that EGFR tyrosine kinase inhibitors may represent 
a therapeutic option for patients with multiple lesions in numer-
ous lobes, who fulfill the abovementioned criteria.
There are several limitations in our study. First, mea-
surement errors should be considered. There are several 
reports on measurement errors. Johnsson et al.24 reported 
that the 95% limits of agreement concerning the mean of the 
observers measurement were ± 2.1 mm. Oda et al.25 suggested 
that the threshold for identifying an increase in the measured 
volume of a GGO nodule is a 30% increase, based on their 
data of intraobserver and interobserver measurement errors. 
Especially in our study, a part of lesions were examined with 
single-detector CT during the early period of follow-up. 
Second, the results were based on the lesions of highly selected 
patients because our study was retrospectively designed.
Some small lung lesions that exhibited GGO on CT 
persisted without changing in size, whereas others gradually 
grew in size over time. The tendency to grow became clear 
within the first 3 years of observation in all cases. Therefore, 
we conclude that such lesions should be followed for at least 3 
years to best monitor lesion growth.
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